Innate and adaptive immunity in calcific aortic valve disease

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Mathieu, Patrick ^a   Bouchareb, Rihab ^a   Boulanger, Marie Chloé ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ARACHIDONATE 5 LIPOXYGENASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; E1A ASSOCIATED P300 PROTEIN; GLYCOSAMINOGLYCAN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LEUKOTRIENE; LIPOXYGENASE; NOTCH1 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATE; PURINERGIC P2Y2 RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; AORTIC VALVE DISEASE 1; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; AORTA STENOSIS; AORTA VALVE; AORTA VALVE DISEASE; APOPTOSIS; CALCIFIC AORTA VALVE DISEASE; CALCIFICATION; CARDIOVASCULAR RISK; ELASTIC FIBER; HEART LEFT VENTRICLE; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; LIPID METABOLISM; MINERALIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; AORTA VALVE STENOSIS; CALCINOSIS; CONGENITAL HEART MALFORMATION; IMMUNOLOGY; PATHOLOGY; VALVULAR HEART DISEASE;

ADAPTIVE IMMUNITY; ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-6; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929999005     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/851945     Document Type: Review

References (103)

1. P. Mathieu, M. C. Boulanger, and R. Bouchareb, "Molecular biology of calcific aortic valve disease: towards new pharmacological therapies, " Expert Review of CardiovascularTherapy, vol. 12, no. 7, pp. 851-862, 2014.
2. N. M. Rajamannan, F. J. Evans, E. Aikawa et al., "Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research fromthe national heart and lung and blood institute aortic stenosis working group. Executive summary: calcific aortic valve disease-2011 update, " Circulation, vol. 124, no. 16, pp. 1783-1791, 2011.
3. V. Persy and P. D'Haese, "Vascular calcification and bone disease: the calcification paradox, " Trends in Molecular Medicine, vol. 15, no. 9, pp. 405-416, 2009.
4. R. Bouchareb, M.-C. Boulanger, D. Fournier, P. Pibarot, Y. Messaddeq, and P. Mathieu, "Mechanical strain induces the production of spheroid mineralized microparticles in the aortic valve through a RhoA/ROCK-dependent mechanism, " Journal of Molecular and Cellular Cardiology, vol. 67, pp. 49-59, 2014.
5. K. D. O'Brien, D. D. Reichenbach, S. M. Marcovina, J. Kuusisto, C. E. Alpers, and C. M. Otto, "Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 4, pp. 523-532, 1996.
6. N. Cot, A.Mahmut, Y. Bosse et al., "Inflammation is associated with the remodeling of calcific aortic valve disease, " Inflammation, vol. 36, no. 3, pp. 573-581, 2013.
7. J.-H. Chen and C. A. Simmons, "Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues, " Circulation Research, vol. 108, no. 12, pp. 1510-1524, 2011.
8. J. T. Butcher, C. A. Simmons, and J. N. Warnock, "Mechanobiology of the aortic heart valve, " Journal of Heart Valve Disease, vol. 17, no. 1, pp. 62-73, 2008.
9. P. F. Davies, A. G. Passerini, and C. A. Simmons, "Aortic valve: turning over a new leaf(let) in endothelial phenotypic heterogeneity, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 8, pp. 1331-1333, 2004.
10. D. Mohty, P. Pibarot, J.-P. Desprs et al., "Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 187-193, 2008.
11. C. M. Otto, J. Kuusisto, D. D. Reichenbach, A. M. Gown, and K. D. O'Brien, "Characterization of the early lesion of 'degenerative' valvular aortic stenosis: histological and immunohistochemical studies, " Circulation, vol. 90, no. 2, pp. 844-853, 1994.
12. I. Steiner, P. Kasparov, A. Kohout, and J. Dominik, "Bone formation in cardiac valves: a histopathological study of 128 cases, " Virchows Archiv, vol. 450, no. 6, pp. 653-657, 2007.
13. A. R. Brasier, "The nuclear factor-B-interleukin-6 signalling pathway mediating vascular inflammation, " Cardiovascular Research, vol. 86, no. 2, pp. 211-218, 2010.
14. F. Liu, Y. Xia, A. S. Parker, and I. M. Verma, "IKK biology, " Immunological Reviews, vol. 246, no. 1, pp. 239-253, 2012.
15. A. A. Beg, T. S. Finco, P. V. Nantermet, and A. S. Baldwin Jr., "Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IB: a mechanism for NF-B activation, " Molecular andCellular Biology, vol. 13, no. 6, pp. 3301-3310, 1993.
16. K. Hochrainer, G. Racchumi, and J. Anrather, "Site-specific phosphorylation of the p65 protein subunit mediates selective gene expression by differential NF-B and RNA polymerase II promoter recruitment, " The Journal of Biological Chemistry, vol. 288, no. 1, pp. 285-293, 2013.
17. C. C. Ghosh, S. Ramaswami, A. Juvekar et al., "Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IB, " Journal of Immunology, vol. 185, no. 6, pp. 3685-3693, 2010.
18. H. Zhong, R. E. Voll, and S. Ghosh, "Phosphorylation of NF-B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300, " Molecular Cell, vol. 1, no. 5, pp. 661-671, 1998.
19. M. Jamaluddin, S.Wang, I. Boldogh, B. Tian, and A. R. Brasier, "TNF-induced NF-B/RelA Ser276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway, " Cellular Signalling, vol. 19, no. 7, pp. 1419-1433, 2007.
20. E. Branchetti, R. Sainger, P. Poggio et al., "Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. e66-e74, 2013.
21. G. Xiao, A. Fong, and S.-C. Sun, "Induction of p100 processing by NF-B-inducing kinase involves docking IB kinase (IKK) to p100 and IKK-mediated phosphorylation, " Journal of Biological Chemistry, vol. 279, no. 29, pp. 30099-30105, 2004.
22. M. D. Morrison, W. Reiley, M. Zhang, and S.-C. Sun, "An atypical Tumor Necrosis Factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF Family (BAFF) receptor mediates induction of the noncanonical NF-B signaling pathway, " Journal of Biological Chemistry, vol. 280, no. 11, pp. 10018-10024, 2005.
23. D. El Husseini, M.-C. Boulanger, A. Mahmut et al., "P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease, " Journal of Molecular and Cellular Cardiology, vol. 72, pp. 146-156, 2014.
24. N. Côt, D. El Husseini, A. Ppin et al., "ATP acts as a survival signal and prevents the mineralization of aortic valve, " Journal of Molecular and Cellular Cardiology, vol. 52, no. 5, pp. 1191-1202, May 2012.
25. P. Mathieu, P. Voisine, A. Ppin, R. Shetty, N. Savard, and F. Dagenais, "Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity, " Journal of Heart Valve Disease, vol. 14, no. 3, pp. 353-357, 2005.
26. N. Côt, D. El Husseini, A. Ppin et al., "Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats, " European Journal of Pharmacology, vol. 689, no. 1-3, pp. 139-146, 2012.
27. P. Mathieu, "Pharmacology of ectonucleotidases: relevance for the treatment of cardiovascular disorders, " European Journal of Pharmacology, vol. 696, no. 1-3, pp. 1-4, 2012.
28. D. El Husseini, M.-C. Boulanger, D. Fournier et al., "High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1, " PLoS ONE, vol. 8, no. 1, Article ID e53393, 2013.
29. P. Mathieu, I. Lemieux, and J.-P. Desprs, "Obesity, inflammation, and cardiovascular risk, " Clinical Pharmacology & Therapeutics, vol. 87, no. 4, pp. 407-416, 2010.
30. G. J. Mahler, E. J. Farrar, and J. T. Butcher, "Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 1, pp. 121-130, 2013.
31. T. Wada, T. Nakashima, N. Hiroshi, and J. M. Penninger, "RANKL-RANK signaling in osteoclastogenesis and bone disease, " Trends in Molecular Medicine, vol. 12, no. 1, pp. 17-25, 2006.
32. P. Mathieu, P. Poirier, P. Pibarot, I. Lemieux, and J.-P. Desprs, "Visceral obesity the link among inflammation, hypertension, and cardiovascular disease, " Hypertension, vol. 53, no. 4, pp. 577-584, 2009.
33. Z. Yu, K. Seya, K. Daitoku, S. Motomura, I. Fukuda, and K.-I. Furukawa, "Tumor necrosis factor-accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway, " Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 1, pp. 16-23, 2011.
34. J. J. Kaden, R. Kilic A. Sarikocet al., "Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification, " International Journal of Molecular Medicine, vol. 16, no. 5, pp. 869-872, 2005.
35. R. A. Black, C. T. Rauch, C. J. Kozlosky et al., "A metalloproteinase disintegrin that releases tumour-necrosis factor-from cells, " Nature, vol. 385, no. 6618, pp. 729-733, 1997.
36. H. Hsu, J. Xiong, and D. V. Goeddel, "The TNF receptor 1-associated protein TRADD signals cell death and NF-B activation, " Cell, vol. 81, no. 4, pp. 495-504, 1995.
37. H. Hsu, H.-B. Shu, M.-G. Pan, and D. V. Goeddel, "TRADDTRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways, " Cell, vol. 84, no. 2, pp. 299-308, 1996.
38. S. Bertazzo, E. Gentleman, K. L. Cloyd, A. H. Chester, M. H. Yacoub, and M. M. Stevens, "Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification, " Nature Materials, vol. 12, no. 6, pp. 576-583, 2013.
39. A. Adhikari, M. Xu, and Z. J. Chen, "Ubiquitin-mediated activation of TAK1 and IKK, " Oncogene, vol. 26, no. 22, pp. 3214-3226, 2007.
40. H.-L. Lee, K. M. Woo, H.-M. Ryoo, and J.-H. Baek, "Tumor necrosis factor-increases alkaline phosphatase expression in vascular smoothmuscle cells via MSX2 induction, " Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 1087-1092, 2010.
41. Z. Al-Aly, J.-S. Shao, C.-F. Lai et al., "Aortic Msx2-Wnt calcification cascade is regulated by TNF-dependent signals in diabetic Ldlr/mice, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2589-2596, 2007.
42. K. Isoda, T. Matsuki, H. Kondo, Y. Iwakura, and F. Ohsuzu, "Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/cMice, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 4, pp. 708-715, 2010.
43. J. J. Kaden, C.-E. Dempfle, R. Grobholz et al., "Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis, " Atherosclerosis, vol. 170, no. 2, pp. 205-211, 2003.
44. A. Galeone, G. Brunetti, A. Oranger et al., "Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand, " International Journal of Cardiology, vol. 169, no. 4, pp. 296-304, 2013.
45. L. Lum, B. R. Wong, R. Josien et al., "Evidence for a role of a tumor necrosis factor-(TNF-)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival, " Journal of Biological Chemistry, vol. 274, no. 19, pp. 13613-13618, 1999.
46. B. R. Wong, R. Josien, S. Y. Lee, M. Vologodskaia, R. M. Steinman, and Y. Choi, "The TRAF family of signal transducers mediates NF-B activation by the TRANCE receptor, " The Journal of Biological Chemistry, vol. 273, no. 43, pp. 28355-28359, 1998.
47. B. R. Wong, D. Besser, N. Kim et al., "TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src, " Molecular Cell, vol. 4, no. 6, pp. 1041-1049, 1999.
48. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, " Cell, vol. 89, no. 2, pp. 309-319, 1997.
49. N. Bucay, I. Sarosi, C. R. Dunstan et al., "Osteoprotegerindeficient mice develop early onset osteoporosis and arterial calcification, " Genes and Development, vol. 12, no. 9, pp. 1260-1268, 1998.
50. J. J.Kaden, S. Bickelhaupt, R.Grobholz et al., "Receptor activator of nuclear factor B ligand and osteoprotegerin regulate aortic valve calcification, " Journal of Molecular and Cellular Cardiology, vol. 36, no. 1, pp. 57-66, 2004.
51. R. M. Weiss, D. D. Lund, Y. Chu et al., "Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice, " PLoS ONE, vol. 8, no. 6, Article ID e65201, 2013.
52. K. D.O'Brien, D. M. Shavelle, M. T. Caulfield et al., "Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma, " Circulation, vol. 106, no. 17, pp. 2224-2230, 2002.
53. S. Helske, K. A. Lindstedt, M. Laine et al., "Induction of local angiotensin II-producing systems in stenotic aortic valves, " Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1859-1866, 2004.
54. E. Wypasek, J. Natorska, G. Grudzie, G. Filip, J. Sadowski, and A. Undas, "Mast cells in human stenotic aortic valves are associated with the severity of stenosis, " Inflammation, vol. 36, no. 2, pp. 449-456, 2013.
55. N. Côt, P. Pibarot, A. Ppin et al., "Oxidized low-density lipoprotein, angiotensin II and increasedwaist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis, " International Journal of Cardiology, vol. 145, no. 3, pp. 444-449, 2010.
56. N. Côt, A. Mahmut, D. Fournier et al., "Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease, " Pathobiology, vol. 81, no. 1, pp. 15-24, 2013.
57. R. Capoulade, M.-A. Clavel, P. Mathieu et al., "Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis, " European Journal of Clinical Investigation, vol. 43, no. 12, pp. 1262-1272, 2013.
58. T. Fujisaka, M. Hoshiga, J. Hotchi et al., "Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice, " Atherosclerosis, vol. 226, no. 1, pp. 82-87, 2013.
59. K. Arishiro, M. Hoshiga, N. Negoro et al., "Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits, " Journal of the American College of Cardiology, vol. 49, no. 13, pp. 1482-1489, 2007.
60. L. M. McAllister-Lucas, J. Ruland, K. Siu et al., "CARMA3/Bcl10/MALT1-dependent NF-B activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 139-144, 2007.
61. S. Choudhary, M. Lu, R. Cui, and A. R. Brasier, "Involvement of a novel Rac/RhoA guanosine triphosphatase-nuclear factor-B inducing kinase signaling pathwaymediating angiotensin IIinduced RelA transactivation, "Molecular Endocrinology, vol. 21, no. 9, pp. 2203-2217, 2007.
62. C. Y. Sasaki, T. J. Barberi, P. Ghosh, and D. L. Longo, "Phosphorylation of Re1A/p65 on serine 536 defines an IB-independent NF-B pathway, " Journal of Biological Chemistry, vol. 280, no. 41, pp. 34538-34547, 2005.
63. D. Bosisio, I.Marazzi, A.Agresti, N. Shimizu, M. E. Bianchi, and G. Natoli, "A hyper-dynamic equilibrium between promoterbound and nucleoplasmic dimers controls NF-B-dependent gene activity, " The EMBO Journal, vol. 25, no. 4, pp. 798-810, 2006.
64. M. Olsson, J. Thyberg, and J. Nilsson, "Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1218-1222, 1999.
65. M. Briand, I. Lemieux, J. G. Dumesnil et al., "Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis, " Journal of theAmericanCollege of Cardiology, vol. 47, no. 11, pp. 2229-2236, 2006.
66. A. Mahmut, M.-C. Boulanger, D. Fournier et al., "Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling, " European Journal of Clinical Investigation, vol. 43, no. 6, pp. 570-578, 2013.
67. H. Derbali, Y. Bosse, N. Cote et al., "Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via toll-like receptor 2, " The American Journal of Pathology, vol. 176, no. 6, pp. 2638-2645, 2010.
68. R. Song, Q. Zeng, L. Ao et al., "Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via toll-like receptor-2, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2711-2720, 2012.
69. R. Song, L. Ao, K.-S. Zhao et al., "Soluble biglycan induces the production of ICAM-1 and MCP-1 in human aortic valve interstitial cells through TLR2/4 and the ERK1/2 pathway, " Inflammation Research, vol. 63, no. 9, pp. 703-710, 2014.
70. N. A. Nadlonek, J. H. Lee, M. J. Weyant, X. Meng, and D. A. Fullerton, "Ox-LDL induces PiT-1 expression in human aortic valve interstitial cells, " Journal of Surgical Research, vol. 184, no. 1, pp. 6-9, 2013.
71. Q. Zeng, R. Song, L. Ao et al., "Notch1 promotes the proosteogenic response of human aortic valve interstitial cells via modulation of erk1/2 and nuclear factor-b activation, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 7, pp. 1580-1590, 2013.
72. Q. Zeng, C. Jin, L. Ao et al., "Cross-talk between the toll-like receptor 4 and notch1 pathways augments the inflammatory response in the interstitial cells of stenotic human aortic valves, " Circulation, vol. 126, no. 11, supplement 1, pp. S222-S230, 2012.
73. V. Garg, A.N.Muth, J. F. Ransom et al., "Mutations inNOTCH1 cause aortic valve disease, " Nature, vol. 437, no. 7056, pp. 270-274, 2005.
74. V. Nigam and D. Srivastava, "Notch1 represses osteogenic pathways in aortic valve cells, " Journal ofMolecular and Cellular Cardiology, vol. 47, no. 6, pp. 828-834, 2009.
75. N. Osman, K. J. Grande-Allen, M. L. Ballinger et al., "Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans, " Cardiovascular Pathology, vol. 22, no. 2, pp. 146-155, 2013.
76. J. D. Miller, Y. Chu, R. M. Brooks, W. E. Richenbacher, R. Peña-Silva, and D. D. Heistad, "Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans, " Journal of the American College of Cardiology, vol. 52, no. 10, pp. 843-850, 2008.
77. H. Li and U. Forstermann, "Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease, " Current Opinion in Pharmacology, vol. 13, no. 2, pp. 161-167, 2013.
78. G.Thanassoulis, C. Y. Campbell, D. S. Owens et al., "Genetic associations with valvular calcification and aortic stenosis, " The New England Journal of Medicine, vol. 368, no. 6, pp. 503-512, 2013.
79. P. R. Kamstrup, A. Tybjg-Hansen, and B. G. Nordestgaard, "Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population, " Journal of the American College of Cardiology, vol. 63, no. 5, pp. 470-477, 2014.
80. B. J. Arsenault, S. M. Boekholdt, M. P. Dube et al., "Lipoprotein( a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort, " Circulation: Cardiovascular Genetics, vol. 7, no. 3, pp. 304-310, 2014.
81. M.-Y. Hung, J. L. Witztum, and S. Tsimikas, "New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis, " Journal of the American College of Cardiology, vol. 63, no. 5, pp. 478-480, 2014.
82. Y. I.Miller, S.-H.Choi, P.Wiesner et al., "Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity, " Circulation Research, vol. 108, no. 2, pp. 235-248, 2011.
83. A. Mahmut, M.-C. Boulanger, D. El Husseini et al., "Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization, " Journal of the American College of Cardiology, vol. 63, no. 5, pp. 460-469, 2014.
84. A.Mahmut, H. Mahjoub, M.-C. Boulanger et al., "Lp-PLA2 is associated with structural valve degeneration of bioprostheses, " European Journal of Clinical Investigation, vol. 44, no. 2, pp. 136-145, 2014.
85. E.Nagy, D. C. Andersson, K. Caidahl et al., "Upregulationof the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts, " Circulation, vol. 123, no. 12, pp. 1316-1325, 2011.
86. D. Poeckel and C. D. Funk, "The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease, " Cardiovascular Research, vol. 86, no. 2, pp. 243-253, 2010.
87. J. H. Chen, W. L. K. Chen, K. L. Sider, C. Y. Yip, and C. A. Simmons, "-catenin mediates mechanically regulated, transforming growth factor-1-induced myofibroblast differentiation of aortic valve interstitial cells, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 590-597, 2011.
88. J.D.Hutcheson, L. M. Ryzhova, V. Setola, andW.D.Merryman, "5-HT2 antagonism arrests non-canonical TGF-1-induced valvularmyofibroblast differentiation, " Journal ofMolecular and Cellular Cardiology, vol. 53, no. 5, pp. 707-714, 2012.
89. A.Mazzone, M. C. Epistolato, R. De Caterina et al., "Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis, " Journal of the American College of Cardiology, vol. 43, no. 9, pp. 1670-1676, 2004.
90. A. Charest, A. Ppin, R. Shetty et al., "Distribution of SPARC during neovascularisation of degenerative aortic stenosis, " Heart, vol. 92, no. 12, pp. 1844-1849, 2006.
91. M. Yoshioka, S. Yuasa, K.Matsumura et al., "Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis, " Nature Medicine, vol. 12, no. 10, pp. 1151-1159, 2006.
92. O. Fondard, D. Detaint, B. Iung et al., "Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors, " European Heart Journal, vol. 26, no. 13, pp. 1333-1341, 2005.
93. I. Perrotta, E. Russo, C. Camastra et al., "New evidence for a critical role of elastin in calcification of native heart valves: Immunohistochemical and ultrastructural study with literature review, " Histopathology, vol. 59, no. 3, pp. 504-513, 2011.
94. S. Helske, S. Syvranta, K. A. Lindstedt et al., "Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1791-1798, 2006.
95. E. Aikawa, M. Aikawa, G. Rusanescu et al., "Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease, " Circulation, vol. 119, no. 13, pp. 1785-1794, 2009.
96. R.Winchester, M.Wiesendanger, W.O'Brien et al., "Circulating activated and effector memory T cells are associated with calcification and clonal expansions in bicuspid and tricuspid valves of calcific aortic stenosis, " Journal of Immunology, vol. 187, no. 2, pp. 1006-1014, 2011.
97. H.D.Wu, M. S.Maurer, R. A. Friedman et al., "The lymphocytic infiltration in calcific aortic stenosis predominantly consists of clonally expanded T cells, " The Journal of Immunology, vol. 178, no. 8, pp. 5329-5339, 2007.
98. R. Wu, R. Giscombe, G. Holm, and A. K. Lefvert, "Induction of human cytotoxic T lymphocytes by oxidized low density lipoproteins, " Scandinavian Journal of Immunology, vol. 43, no. 4, pp. 381-384, 1996.
99. C. Cote, P. Pibarot, J. P. Despres et al., "Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis, " Heart, vol. 94, no. 9, pp. 1175-1180, 2008.
100. S. Stemme, B. Faber, J. Holm, O. Wiklund, J. L. Witztum, and G. K. Hansson, "T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein, " Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 3893-3897, 1995.
101. P. M. Ridker, "Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT), " Journal of Thrombosis and Haemostasis, vol. 7, supplement 1, pp. 332-339, 2009.
102. A. Bulgarelli, A. A. Martins Dias, B. Caramelli, and R. C. Maranhaõ, "Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits, " Journal of Cardiovascular Pharmacology, vol. 59, no. 4, pp. 308-314, 2012.
103. M. R. Hurle, L. Yang, Q. Xie, D. K. Rajpal, P. Sanseau, and P. Agarwal, "Computational drug repositioning: from data to therapeutics, " Clinical Pharmacology Therapeutics, vol. 93, no. 4, pp. 335-341, 2013.